<DOC>
	<DOC>NCT01827579</DOC>
	<brief_summary>The purpose of this study is to evaluate whether the administration of allodepleted donor T cells to patients with haematological malignancies after stem cell transplant can improve the recovery of the patients immune system.</brief_summary>
	<brief_title>Infusion of Depleted T Cells Following Unrelated Donor Stem Cell Transplant (ICAT)</brief_title>
	<detailed_description />
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<criteria>Age â‰¥16 years Underlying haematological malignancy Planned allogeneic peripheral blood stem cell transplantation from a 10/10 or 9/10 HLA matched unrelated donor, using an Alemtuzumabbased conditioning protocol Written Informed consent Life expectancy &lt; 6 weeks Female patients who are pregnant and lactating Patients who are serologically positive for Hepatitis B, C or HIV preSCT</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Transplant</keyword>
	<keyword>CD25/71 allodepleted donor T cells</keyword>
	<keyword>Infection</keyword>
	<keyword>Acute Myeloid Leukaemia</keyword>
	<keyword>Acute Lymphoblastic Leukaemia</keyword>
	<keyword>Adult</keyword>
	<keyword>Diffuse Large B-Cell Lymphoma</keyword>
	<keyword>Mantle Cell Lymphoma</keyword>
</DOC>